- Home
- BMEA vs PRLD Comparison
BMEA vs PRLD Comparison
Compare BMEA & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMEA
- PRLD
- Stock Information
- Founded
- BMEA 2017
- PRLD 2016
- Country
- BMEA United States
- PRLD United States
- Employees
- BMEA N/A
- PRLD N/A
- Industry
- BMEA Biotechnology: Pharmaceutical Preparations
- PRLD Medicinal Chemicals and Botanical Products
- Sector
- BMEA Health Care
- PRLD Health Care
- Exchange
- BMEA Nasdaq
- PRLD Nasdaq
- Market Cap
- BMEA 275.6M
- PRLD 110.0M
- IPO Year
- BMEA 2021
- PRLD 2020
- Fundamental
- Price
- BMEA $11.42
- PRLD $1.92
- Analyst Decision
- BMEA Buy
- PRLD Buy
- Analyst Count
- BMEA 13
- PRLD 3
- Target Price
- BMEA $36.33
- PRLD $5.33
- AVG Volume (30 Days)
- BMEA 1.0M
- PRLD 231.0K
- Earning Date
- BMEA 10-28-2024
- PRLD 10-30-2024
- Dividend Yield
- BMEA N/A
- PRLD N/A
- EPS Growth
- BMEA N/A
- PRLD N/A
- EPS
- BMEA N/A
- PRLD N/A
- Revenue
- BMEA N/A
- PRLD N/A
- Revenue This Year
- BMEA N/A
- PRLD N/A
- Revenue Next Year
- BMEA N/A
- PRLD N/A
- P/E Ratio
- BMEA N/A
- PRLD N/A
- Revenue Growth
- BMEA N/A
- PRLD N/A
- 52 Week Low
- BMEA $3.61
- PRLD $1.66
- 52 Week High
- BMEA $22.74
- PRLD $6.80
- Technical
- Relative Strength Index (RSI)
- BMEA 68.67
- PRLD 30.18
- Support Level
- BMEA $10.35
- PRLD $1.87
- Resistance Level
- BMEA $11.83
- PRLD $2.01
- Average True Range (ATR)
- BMEA 0.93
- PRLD 0.12
- MACD
- BMEA 0.02
- PRLD 0.10
- Stochastic Oscillator
- BMEA 58.54
- PRLD 29.41
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.